VEGFA and pulmonary arterial hypertension: Overall, these results confirm that in addition to BMPR2 silencing, HPAECs treated with VEGF, another known PAH-inducing cellular mechanism, leads to endothelial dysfunction and hyper-migration mediated by the nmMLCK pathway.